These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 25743376)

  • 21. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
    Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
    Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study.
    Yao W; Wang C; Zhong N; Han X; Wu C; Yan X; Chen P; Yang W; Henley M; Kramer B
    Respirology; 2014 Feb; 19(2):231-238. PubMed ID: 24383720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.
    Geake JB; Dabscheck EJ; Wood-Baker R; Cates CJ
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010139. PubMed ID: 25575340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM; Williams J
    Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
    Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ; Yoon HK; Park MJ; Yoo KH; Jung KS; Park JW; Lim SY; Shim JJ; Lee YC; Kim YS; Oh YM; Kim S; Yoo CG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1589-1596. PubMed ID: 28615931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
    Cazzola M; Rogliani P; Ruggeri P; Segreti A; Proietto A; Picciolo S; Matera MG
    Respir Med; 2013 Jun; 107(6):848-53. PubMed ID: 23490225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease.
    Matsushima S; Inui N; Yasui H; Kono M; Nakamura Y; Toyoshima M; Shirai T; Suda T
    Pulm Pharmacol Ther; 2015 Feb; 30():11-5. PubMed ID: 25445929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
    Barnes PJ; Pocock SJ; Magnussen H; Iqbal A; Kramer B; Higgins M; Lawrence D
    Pulm Pharmacol Ther; 2010 Jun; 23(3):165-71. PubMed ID: 20080201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
    Cope S; Donohue JF; Jansen JP; Kraemer M; Capkun-Niggli G; Baldwin M; Buckley F; Ellis A; Jones P
    Respir Res; 2013 Oct; 14(1):100. PubMed ID: 24093477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
    Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
    Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
    Beier J; Beeh KM; Brookman L; Peachey G; Hmissi A; Pascoe S
    Pulm Pharmacol Ther; 2009 Dec; 22(6):492-6. PubMed ID: 19465142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.
    Rossi A; van der Molen T; del Olmo R; Papi A; Wehbe L; Quinn M; Lu C; Young D; Cameron R; Bucchioni E; Altman P
    Eur Respir J; 2014 Dec; 44(6):1548-56. PubMed ID: 25359348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
    Mahler DA; D'Urzo A; Bateman ED; Ozkan SA; White T; Peckitt C; Lassen C; Kramer B;
    Thorax; 2012 Sep; 67(9):781-8. PubMed ID: 22544891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
    Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
    Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.